Population Pharmacokinetics of Isavuconazole in Critical Care Patients with COVID-19-Associated Pulmonary Aspergillosis and Monte Carlo Simulations of High Off-Label Doses

Isavuconazole is a triazole antifungal agent recently recommended as first-line therapy for invasive pulmonary aspergillosis. With the COVID-19 pandemic, cases of COVID-19-associated pulmonary aspergillosis (CAPA) have been described with a prevalence ranging from 5 to 30%. We developed and validate...

Descripción completa

Detalles Bibliográficos
Autores principales: Perez, Lucas, Corne, Philippe, Pasquier, Grégoire, Konecki, Céline, Sadek, Meriem, Le Bihan, Clément, Klouche, Kada, Mathieu, Olivier, Reynes, Jacques, Cazaubon, Yoann
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960864/
https://www.ncbi.nlm.nih.gov/pubmed/36836325
http://dx.doi.org/10.3390/jof9020211

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960864/
https://www.ncbi.nlm.nih.gov/pubmed/36836325
http://dx.doi.org/10.3390/jof9020211

Ejemplares similares